Name: Macular Degeneration Treatment Market Size, Share & Trends Analysis Report, By Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), By Treatment Type (Anti-VEGF Therapy, Photodynamic Therapy, Laser Therapy, Nutritional Supplements, Emerging Therapies), By Drug Class (VEGF Inhibitors, Complement Inhibitors, Corticosteroids, Combination Therapies), By Route of Administration (Intravitreal, Intravenous), Forecast Period (2026-2035)
Brand: Orion Market Research
SKU: OMR2029476
Price: 2400 USD
Availability: InStock

Macular Degeneration Treatment Market

SHARE ON:

Macular Degeneration Treatment Market Size, Share & Trends Analysis Report, By Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), By Treatment Type (Anti-VEGF Therapy, Photodynamic Therapy, Laser Therapy, Nutritional Supplements, Emerging Therapies), By Drug Class (VEGF Inhibitors, Complement Inhibitors, Corticosteroids, Combination Therapies), By Route of Administration (Intravitreal, Intravenous), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2029476 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Macular degeneration treatment market was valued at $18.8 billion in 2025 and is projected to reach $33.7 billion by 2035, expanding at a CAGR of 6.0% during 2026–2035. The market is primarily driven by the rising prevalence of age-related macular degeneration (AMD), particularly among aging populations globally.

According to the World Health Organization (WHO), approximately 2.2 billion people globally suffer from vision impairment, with AMD being one of the leading causes of blindness in individuals aged over 60. Additionally, data from the International Agency for the Prevention of Blindness (IAPB) highlights that AMD contributes significantly to irreversible vision loss in developed economies.

The increasing adoption of anti-VEGF therapies, advancements in biologics, and growing awareness regarding early diagnosis are key factors accelerating market growth. Pharmaceutical companies are investing heavily in long-acting retinal therapies and complement inhibitors, reshaping the competitive landscape. Major end-use sectors include hospitals, ophthalmology clinics, and ambulatory surgical centers, which are witnessing rising patient volumes globally.

Market Dynamics

Rising Aging Population and Increasing Prevalence of Retinal Disorders Drive Market Growth

The growth of the macular degeneration treatment market is significantly driven by the rising geriatric population globally. According to the United Nations (UN), the global population aged 65 and above is expected to reach 2.2 billion by 2070, increasing the patient pool susceptible to AMD. Furthermore, data from the OECD indicates that healthcare expenditure on age-related diseases has increased by over 20% in the last decade, reflecting the growing burden on healthcare systems.

The increasing demand for anti-VEGF injections, which require repeated administration, is creating a steady revenue stream for pharmaceutical companies. In 2025–2026, companies are focusing on extended-duration therapies to reduce injection frequency and improve patient compliance. Additionally, regulatory approvals from the U.S. Food and Drug Administration (FDA) for innovative biologics are accelerating market expansion.

High Treatment Costs and Limited Access in Developing Regions Pose Challenges

Despite strong growth prospects, the market faces challenges related to high treatment costs and accessibility issues. Anti-VEGF therapies can cost thousands of dollars annually per patient, limiting adoption in low- and middle-income countries. According to the World Bank, nearly 40% of the global population lacks access to essential healthcare services, which directly impacts the adoption of advanced AMD treatments.

Supply chain complexities, including biologics manufacturing and cold chain logistics, further add to operational costs. Additionally, the entry of biosimilars is creating pricing pressure, impacting revenue margins for key players. However, companies are responding through cost optimization strategies, partnerships, and localized manufacturing, particularly in the Asia-Pacific regions.

Market Segmentation

Based on the type, the market is segmented into dry age-related macular degeneration (dry AMD) and wet age-related macular degeneration (wet AMD).
Based on the treatment type, the market is segmented into anti-VEGF therapy, photodynamic therapy (PDT), laser therapy, nutritional supplements, and emerging therapies.
Based on the drug class, the market is segmented into VEGF inhibitors, complement inhibitors, corticosteroids, and combination therapies.
Based on the route of administration, the market is segmented into intravitreal and intravenous.

Anti-VEGF Therapy Segment Leads the Market

The anti-VEGF therapy segment dominates the macular degeneration treatment market, accounting for the majority of revenue share due to its proven efficacy in treating wet AMD. These therapies inhibit abnormal blood vessel growth, which is the primary cause of vision loss in wet AMD patients. Between 2022 and 2026, pharmaceutical companies have focused on developing long-acting anti-VEGF drugs, reducing the frequency of injections, and improving patient adherence. The widespread adoption of these therapies across hospitals and specialty clinics has further strengthened their market position. Additionally, increasing reimbursement coverage in developed regions has contributed to higher treatment uptake

Complement Inhibitors Segment to Record Strong Growth

The complement inhibitors segment is expected to witness the fastest growth during the forecast period, driven by its application in treating dry AMD, an area with limited therapeutic options. Technological advancements in immunotherapy and increased investment in R&D are driving innovation in this segment. Companies are focusing on targeted therapies that address underlying disease mechanisms, leading to improved clinical outcomes. The growing pipeline of complement inhibitors and favorable regulatory approvals are expected to accelerate adoption, particularly in North America and Europe.

Regional Outlook

The global macular degeneration treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the macular degeneration treatment market due to its advanced healthcare infrastructure and high adoption of innovative therapies. According to the Centers for Disease Control and Prevention (CDC), approximately 20 million Americans suffer from AMD, making it a significant public health concern. Additionally, strong reimbursement policies and the presence of leading pharmaceutical companies support market growth. Continuous investments in R&D and early adoption of advanced biologics further strengthen the country’s leadership position.

China to Record Strong Growth

China is expected to witness the fastest growth due to increasing healthcare investments and a rapidly aging population. According to the National Bureau of Statistics of China, individuals aged 60 and above accounted for over 19% of the population in 2024, significantly increasing AMD prevalence. Additionally, expanding healthcare infrastructure and rising awareness regarding eye diseases are driving treatment adoption. Government initiatives to improve healthcare access and growing pharmaceutical manufacturing capabilities are further boosting market growth.

Market Player Outlook

The macular degeneration treatment market is highly competitive and characterized by the presence of major pharmaceutical companies focusing on biologics and innovative retinal therapies. Companies are investing in research and development, strategic collaborations, and product differentiation to gain a competitive edge.

Key players such as Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche (Genentech), Bayer AG, Novartis AG, and Apellis Pharmaceuticals dominate the market through strong product portfolios and global distribution networks. The competition is primarily driven by drug efficacy, duration of action, pricing strategies, and regulatory approvals. Additionally, the entry of biosimilars is reshaping competitive dynamics, encouraging companies to innovate continuously.

Recent Developments

In January 2025, Regeneron Pharmaceuticals strengthened its position in the macular degeneration treatment market through continued leadership of its anti-VEGF portfolio, with EYLEA and EYLEA HD generating $6 billion in U.S. sales in 2024. The company is advancing lifecycle innovations, including a pre-filled syringe launch expected in 2025 and extended dosing intervals under regulatory review for improved patient convenience.
In May 2024, Johnson & Johnson is advancing innovation in the Macular Degeneration Treatment Market through its latest research showcased at ARVO 2024, focusing on AI-driven diagnostic tools and early genetic testing to improve disease detection and reduce healthcare costs. The company is also introducing the EYE-RD Global Registry to enhance real-world data collection and understanding of retinal diseases, including advanced stages like geographic atrophy.

The Report Covers

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global macular degeneration treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.

Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Macular Degeneration Treatment Market Sales Analysis – Type | Treatment Type | Drug Class | Route of Administration ($ Million)
Macular Degeneration Treatment Market Sales Performance of Top Countries

1.1 Research Methodology

Primary Research Approach
Secondary Research Approach

1.2 Market Snapshot

Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

??2.2.1 Key Macular Degeneration Treatment Market Trends
??2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Macular Degeneration Treatment Market

??2.3.1 Competitive Rivalry
??2.3.2 Threat of New Entrants
??2.3.3 Bargaining Power of Suppliers
??2.3.4 Bargaining Power of Buyers
??2.3.5 Threat of Substitutes

Market Determinants

3.1 Market Drivers

??3.1.1 Drivers For Global Macular Degeneration Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

??3.2.1 Restraints For Global Macular Degeneration Treatment Market: Impact Analysis

3.3 Market Opportunities

??3.3.1 Opportunities For Global Macular Degeneration Treatment Market: Impact Analysis

Competitive Landscape

4.1 Competitive Dashboard – Macular Degeneration Treatment Market Size, Market Revenue, and Share by Manufacturers

Macular Degeneration Treatment Comparison Analysis
Top Market Player Ranking Matrix

4.2 Key Company Analysis

??4.2.1 Regeneron Pharmaceuticals, Inc.
????4.2.1.1 Overview
????4.2.1.2 Product Portfolio
????4.2.1.3 Financial Analysis
????4.2.1.4 SWOT Analysis
????4.2.1.5 Business Strategy

??4.2.2 F. Hoffmann-La Roche (Genentech)
????4.2.2.1 Overview
????4.2.2.2 Product Portfolio
????4.2.2.3 Financial Analysis
????4.2.2.4 SWOT Analysis
????4.2.2.5 Business Strategy

??4.2.3 Bayer AG
????4.2.3.1 Overview
????4.2.3.2 Product Portfolio
????4.2.3.3 Financial Analysis
????4.2.3.4 SWOT Analysis
????4.2.3.5 Business Strategy

??4.2.4 Novartis AG
????4.2.4.1 Overview
????4.2.4.2 Product Portfolio
????4.2.4.3 Financial Analysis
????4.2.4.4 SWOT Analysis
????4.2.4.5 Business Strategy

??4.2.5 Apellis Pharmaceuticals
????4.2.5.1 Overview
????4.2.5.2 Product Portfolio
????4.2.5.3 Financial Analysis
????4.2.5.4 SWOT Analysis
????4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

??4.3.1 Merger and Acquisition
??4.3.2 Product Launch
??4.3.3 Partnership And Collaboration

Global Macular Degeneration Treatment Market Sales Analysis by Type ($ Million)

5.1 Dry Age-Related Macular Degeneration (Dry AMD)

5.2 Wet Age-Related Macular Degeneration (Wet AMD)

Global Macular Degeneration Treatment Market Sales Analysis by Treatment Type ($ Million)

6.1 Anti-VEGF Therapy

6.2 Photodynamic Therapy (PDT)

6.3 Laser Therapy

6.4 Nutritional Supplements

6.5 Emerging Therapies

Global Macular Degeneration Treatment Market Sales Analysis by Drug Class ($ Million)

7.1 VEGF Inhibitors

7.2 Complement Inhibitors

7.3 Corticosteroids

7.4 Combination Therapies

Global Macular Degeneration Treatment Market Sales Analysis by Route of Administration ($ Million)

8.1 Intravitreal

8.2 Intravenous

Regional Analysis

9.1 North American Macular Degeneration Treatment Market Sales Analysis – Type | Treatment Type | Drug Class | Route of Administration | Country ($ Million)
????9.1.1 United States
????9.1.2 Canada

9.2 European Macular Degeneration Treatment Market Sales Analysis – Type | Treatment Type | Drug Class | Route of Administration | Country ($ Million)
????9.2.1 UK
????9.2.2 Germany
????9.2.3 Italy
????9.2.4 Spain
????9.2.5 France
????9.2.6 Russia
????9.2.7 Rest of Europe

9.3 Asia-Pacific Macular Degeneration Treatment Market Sales Analysis – Type | Treatment Type | Drug Class | Route of Administration | Country ($ Million)
????9.3.1 China
????9.3.2 Japan
????9.3.3 South Korea
????9.3.4 India
????9.3.5 Australia & New Zealand
????9.3.6 ASEAN Countries
????9.3.7 Rest of Asia-Pacific

9.4 Rest of the World Macular Degeneration Treatment Market Sales Analysis – Type | Treatment Type | Drug Class | Route of Administration | Country ($ Million)
????9.4.1 Latin America
????9.4.2 Middle East and Africa

Company Profiles

??10.1 4D Molecular Therapeutics
????10.1.1 Quick Facts
????10.1.2 Company Overview
????10.1.3 Product Portfolio
????10.1.4 Business Strategies

??10.2 Alcon
????10.2.1 Quick Facts
????10.2.2 Company Overview
????10.2.3 Product Portfolio
????10.2.4 Business Strategies

??10.3 Allergan (AbbVie)
????10.3.1 Quick Facts
????10.3.2 Company Overview
????10.3.3 Product Portfolio
????10.3.4 Business Strategies

??10.4 Amgen Inc.
????10.4.1 Quick Facts
????10.4.2 Company Overview
????10.4.3 Product Portfolio
????10.4.4 Business Strategies

??10.5 Annexon Biosciences
????10.5.1 Quick Facts
????10.5.2 Company Overview
????10.5.3 Product Portfolio
????10.5.4 Business Strategies

??10.6 Astellas Pharma Inc. (Iveric Bio)
????10.6.1 Quick Facts
????10.6.2 Company Overview
????10.6.3 Product Portfolio
????10.6.4 Business Strategies

??10.7 Bausch + Lomb
????10.7.1 Quick Facts
????10.7.2 Company Overview
????10.7.3 Product Portfolio
????10.7.4 Business Strategies

??10.8 Biogen Inc. (Samsung Bioepis)
????10.8.1 Quick Facts
????10.8.2 Company Overview
????10.8.3 Product Portfolio
????10.8.4 Business Strategies

??10.9 Clearside Biomedical, Inc.
????10.9.1 Quick Facts
????10.9.2 Company Overview
????10.9.3 Product Portfolio
????10.9.4 Business Strategies

??10.10 Coherus BioSciences, Inc.
????10.10.1 Quick Facts
????10.10.2 Company Overview
????10.10.3 Product Portfolio
????10.10.4 Business Strategies

??10.11 EyeBiotech Limited (EyeBio)
????10.11.1 Quick Facts
????10.11.2 Company Overview
????10.11.3 Product Portfolio
????10.11.4 Business Strategies

??10.12 Graybug Vision (CalciMedica)
????10.12.1 Quick Facts
????10.12.2 Company Overview
????10.12.3 Product Portfolio
????10.12.4 Business Strategies

??10.13 Johnson & Johnson (Janssen)
????10.13.1 Quick Facts
????10.13.2 Company Overview
????10.13.3 Product Portfolio
????10.13.4 Business Strategies

??10.14 Kodiak Sciences Inc.
????10.14.1 Quick Facts
????10.14.2 Company Overview
????10.14.3 Product Portfolio
????10.14.4 Business Strategies

??10.15 LumiThera, Inc.
????10.15.1 Quick Facts
????10.15.2 Company Overview
????10.15.3 Product Portfolio
????10.15.4 Business Strategies

??10.16 Outlook Therapeutics, Inc.
????10.16.1 Quick Facts
????10.16.2 Company Overview
????10.16.3 Product Portfolio
????10.16.4 Business Strategies

??10.17 Oxurion NV
????10.17.1 Quick Facts
????10.17.2 Company Overview
????10.17.3 Product Portfolio
????10.17.4 Business Strategies

??10.18 REGENXBIO Inc.
????10.18.1 Quick Facts
????10.18.2 Company Overview
????10.18.3 Product Portfolio
????10.18.4 Business Strategies

??10.19 Sandoz Group AG
????10.19.1 Quick Facts
????10.19.2 Company Overview
????10.19.3 Product Portfolio
????10.19.4 Business Strategies

??10.20 Viatris Inc.
????10.20.1 Quick Facts
????10.20.2 Company Overview
????10.20.3 Product Portfolio
????10.20.4 Business Strategies

1. Global Macular Degeneration Treatment Market Research and Analysis by Type, 2025–2035 ($ Million)

2. Global Dry Age-Related Macular Degeneration (Dry AMD) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Wet Age-Related Macular Degeneration (Wet AMD) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Macular Degeneration Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

5. Global Anti-VEGF Therapy Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Photodynamic Therapy (PDT) Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Laser Therapy Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Nutritional Supplements Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Emerging Therapies Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Macular Degeneration Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

11. Global VEGF Inhibitors Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Complement Inhibitors Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

13. Global Corticosteroids Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

14. Global Combination Therapies Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

15. Global Macular Degeneration Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

16. Global Intravitreal Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

17. Global Intravenous Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

18. Global Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

19. North America Macular Degeneration Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

20. North America Macular Degeneration Treatment Market Research and Analysis by Type, 2025–2035 ($ Million)

21. North America Macular Degeneration Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

22. North America Macular Degeneration Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

23. North America Macular Degeneration Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

24. Europe Macular Degeneration Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

25. Europe Macular Degeneration Treatment Market Research and Analysis by Type, 2025–2035 ($ Million)

26. Europe Macular Degeneration Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

27. Europe Macular Degeneration Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

28. Europe Macular Degeneration Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

29. Asia-Pacific Macular Degeneration Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

30. Asia-Pacific Macular Degeneration Treatment Market Research and Analysis by Type, 2025–2035 ($ Million)

31. Asia-Pacific Macular Degeneration Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

32. Asia-Pacific Macular Degeneration Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

33. Asia-Pacific Macular Degeneration Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

34. Rest of the World Macular Degeneration Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

35. Rest of the World Macular Degeneration Treatment Market Research and Analysis by Type, 2025–2035 ($ Million)

36. Rest of the World Macular Degeneration Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

37. Rest of the World Macular Degeneration Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

38. Rest of the World Macular Degeneration Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)